Stock ERIS ERIS LIFESCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Eris Lifesciences Limited Bombay S.E.

Equities

ERIS

INE406M01024

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:48 2024-04-30 am EDT 		5-day change 1st Jan Change
891.6 INR -0.34% Intraday chart for Eris Lifesciences Limited +0.91% -2.09%
Apr. 03 Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business MT
Mar. 15 Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion MT

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 88,687 50,089 82,147 93,615 77,801 121,892 - -
Enterprise Value (EV) 1 88,687 50,089 82,147 93,615 85,984 132,330 133,111 127,801
P/E ratio 30.5 x 17.1 x 23.1 x 23 x 20.4 x 29.8 x 27.5 x 21.7 x
Yield - 0.62% 0.91% 0.87% 1.28% 0.76% 0.76% 0.88%
Capitalization / Revenue 9.03 x 4.66 x 6.78 x 6.95 x 4.62 x 6.19 x 4.6 x 4.01 x
EV / Revenue 9.03 x 4.66 x 6.78 x 6.95 x 5.1 x 6.72 x 5.03 x 4.2 x
EV / EBITDA 25.7 x 13.6 x 19.1 x 19.3 x 16 x 18.6 x 13.9 x 11.5 x
EV / FCF 47.9 x 41.8 x 23.5 x 36.4 x -15.6 x -394 x 23.8 x 19.4 x
FCF Yield 2.09% 2.39% 4.26% 2.75% -6.39% -0.25% 4.2% 5.15%
Price to Book 7.71 x 3.86 x 5.21 x 4.91 x 3.54 x 4.83 x 4.24 x 3.62 x
Nbr of stocks (in thousands) 137,520 135,781 135,781 135,930 135,992 136,047 - -
Reference price 2 644.9 368.9 605.0 688.7 572.1 896.0 896.0 896.0
Announcement Date 5/21/19 6/2/20 5/13/21 5/3/22 5/17/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 9,822 10,741 12,119 13,470 16,851 19,706 26,487 30,415
EBITDA 1 3,449 3,683 4,306 4,850 5,367 7,101 9,546 11,077
EBIT 1 3,086 3,180 3,876 4,202 4,197 5,335 7,354 8,625
Operating Margin 31.42% 29.61% 31.98% 31.2% 24.9% 27.07% 27.76% 28.36%
Earnings before Tax (EBT) 1 3,174 3,315 3,945 4,422 4,046 4,707 6,006 7,764
Net income 1 2,908 2,963 3,551 4,061 3,822 4,096 4,378 5,592
Net margin 29.61% 27.59% 29.3% 30.15% 22.68% 20.78% 16.53% 18.39%
EPS 2 21.13 21.58 26.14 29.88 28.07 30.02 32.57 41.23
Free Cash Flow 1 1,850 1,198 3,496 2,572 -5,497 -336 5,593 6,585
FCF margin 18.84% 11.16% 28.85% 19.1% -32.62% -1.71% 21.12% 21.65%
FCF Conversion (EBITDA) 53.63% 32.54% 81.19% 53.04% - - 58.59% 59.45%
FCF Conversion (Net income) 63.62% 40.44% 98.44% 63.34% - - 127.75% 117.76%
Dividend per Share 2 - 2.287 5.500 6.010 7.350 6.766 6.839 7.901
Announcement Date 5/21/19 6/2/20 5/13/21 5/3/22 5/17/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 3,104 2,782 3,437 3,597 3,322 3,059 3,986 4,605 4,233 4,028 4,666 5,094 4,825 5,130
EBITDA 1 1,072 945.2 1,265 1,398 1,217 969 1,292 1,514 1,372 1,189 1,697 1,819 1,740 1,788
EBIT - - - - - - - - - - - - - -
Operating Margin - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 993 847.3 1,171 1,308 1,090 853.4 1,013 1,209 1,065 759 1,125 1,288 1,195 1,102
Net income 1 901.5 682.5 1,067 1,184 1,008 803 945.8 1,203 1,019 654.2 948.6 1,088 1,022 912.4
Net margin 29.04% 24.53% 31.04% 32.92% 30.34% 26.25% 23.73% 26.12% 24.07% 16.24% 20.33% 21.36% 21.18% 17.78%
EPS - - - - - - - - - - - 7.880 - 6.600
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 1/28/21 5/13/21 7/29/21 10/29/21 1/28/22 5/3/22 8/5/22 10/20/22 1/17/23 5/17/23 8/7/23 - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - 8,183 10,438 11,219 5,910
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) - - - - 1.524 x 1.47 x 1.175 x 0.5335 x
Free Cash Flow 1 1,850 1,198 3,496 2,572 -5,497 -336 5,593 6,585
ROE (net income / shareholders' equity) 28.9% 24.2% 24.7% 23.3% 18.6% 17.8% 16.7% 18.3%
ROA (Net income/ Total Assets) - 19.1% - - 12.9% 14.8% 17.6% 18.9%
Assets 1 - 15,535 - - 29,697 27,760 24,872 29,655
Book Value Per Share 2 83.70 95.50 116.0 140.0 161.0 185.0 211.0 247.0
Cash Flow per Share 2 - - 27.60 27.80 21.40 44.70 47.60 56.60
Capex 1 374 1,513 258 1,210 8,414 7,099 1,546 1,824
Capex / Sales 3.81% 14.09% 2.13% 8.99% 49.93% 36.03% 5.84% 6%
Announcement Date 5/21/19 6/2/20 5/13/21 5/3/22 5/17/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Eris Lifesciences Limited

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
896 INR
Average target price
1,081 INR
Spread / Average Target
+20.61%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+34.00% 664B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.29% 567B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.75% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.53% 330B
ABBVIE INC. Stock AbbVie Inc.
+4.95% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.79% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 196B
AMGEN INC. Stock Amgen Inc.
-4.89% 148B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ERIS Stock
  4. ERIS Stock
  5. Financials Eris Lifesciences Limited